Blog

ALLG, in 2024, continues its five decades of impact – Australasian Leukaemia and Lymphoma Group

Photo from Australasian Leukaemia and Lymphoma Group/LinkedIn

Jan 16, 2024, 16:56

ALLG, in 2024, continues its five decades of impact – Australasian Leukaemia and Lymphoma Group

Australasian Leukaemia & Lymphoma Group shared a post on LinkedIn.

“ALLG, in 2024, continues its five decades of impact.
With 6 new blood cancer trials opening in NZ and Australia, we can pursue further research for patients requiring better treatments, better lives.

Working collaboratively with our valued partners both locally and globally, our ultimate aim is to find a cure for this devastating disease.

Our collaborations with European colleagues like Prof Uwe Platzbecker (pictured with Delaine Smith and Prof Judith Trotman) enable us to bring important research to Australia and New Zealand. Visit us to find out more.”

Source: Australasian Leukaemia and Lymphoma Group/LinkedIn

Australasian Leukaemia & Lymphoma Group Australia blood cancer trials cancer Delaine Smith Judith Trotman New Zealand OncoDaily Oncology Uwe Platzbecker

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage